## Carrie C Lubitz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11474646/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Impact of the COVID-19 pandemic on the practice of endocrine surgery. American Journal of Surgery, 2022, 223, 670-675.	1.8	14
2	Four-dimensional computed tomography (4D-CT) for preoperative parathyroid localization: A good study but are we using it?. American Journal of Surgery, 2022, 223, 694-698.	1.8	5
3	Survival After Adrenalectomy for Metastatic Lung Cancer. Annals of Surgical Oncology, 2022, 29, 2571-2579.	1.5	11
4	Smartphone-based Assessment of Preoperative Decision Conflict and Postoperative Physical Activity Among Patients Undergoing Cancer Surgery. Annals of Surgery, 2022, 276, 193-199.	4.2	8
5	ASO Visual Abstract: Survival After Adrenalectomy for Metastatic Lung Cancer. Annals of Surgical Oncology, 2022, , 1.	1.5	0
6	Trends in Thyroid Surgery and Guideline-Concordant Care in the United States, 2007–2018. Thyroid, 2021, 31, 941-949.	4.5	28
7	Smartphone Global Positioning System (GPS) Data Enhances Recovery Assessment After Breast Cancer Surgery. Annals of Surgical Oncology, 2021, 28, 985-994.	1.5	16
8	Non-medullary Thyroid Cancer Susceptibility Genes: Evidence and Disease Spectrum. Annals of Surgical Oncology, 2021, 28, 6590-6600.	1.5	5
9	ASO Visual Abstract: Time to Surgery and Thyroid Cancer Survival in the United States. Annals of Surgical Oncology, 2021, 28, 3566-3566.	1.5	2
10	Time to Surgery and Thyroid Cancer Survival in the United States. Annals of Surgical Oncology, 2021, 28, 3556-3565.	1.5	27
11	ASO Author Reflections: Does Timely Surgery Matter in Papillary Thyroid Cancer?. Annals of Surgical Oncology, 2021, 28, 3567-3567.	1.5	1
12	Progress in Treating Advanced Thyroid Cancers in the Era of Targeted Therapy. Thyroid, 2021, 31, 1451-1462.	4.5	10
13	Expected Versus Experienced Health-Related Quality of Life Among Patients Recovering From Cancer Surgery. Annals of Surgery Open, 2021, 2, e060.	1.4	9
14	Patient Perspectives on the Extent of Surgery and Radioactive Iodine Treatment for Low-Risk Differentiated Thyroid Cancer. Endocrine Practice, 2021, 27, 383-389.	2.1	6
15	American Association of Clinical Endocrinology And Associazione Medici Endocrinologi Thyroid Nodule Algorithmic Tool. Endocrine Practice, 2021, 27, 649-660.	2.1	21
16	Guide to Preoperative Parathyroid Localization Testing. , 2021, , 494-501.e3.		0
17	Adrenalectomy for Secondary Malignancy: Patients, Outcomes, and Indications. Annals of Surgery, 2021, 274, 1073-1080.	4.2	15
18	American Association of Clinical Endocrinology And Associazione Medici Endocrinologi Thyroid Nodule Algorithmic Tool. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2021, 21, 2104-2115.	1.2	2

CARRIE C LUBITZ

#	Article	IF	CITATIONS
19	Financial burden of thyroid cancer in the United States: An estimate of economic and psychological hardship among thyroid cancer survivors. Surgery, 2020, 167, 378-384.	1.9	36
20	Normocalcemic hyperparathyroidism: A Collaborative Endocrine Surgery Quality Improvement Program analysis. Surgery, 2020, 167, 168-172.	1.9	34
21	Using Smartphones to Capture Novel Recovery Metrics After Cancer Surgery. JAMA Surgery, 2020, 155, 123.	4.3	71
22	Primary aldosteronism. Gland Surgery, 2020, 9, 14-24.	1.1	3
23	The American Association of Endocrine Surgeons Guidelines for the Definitive Surgical Management of Thyroid Disease in Adults. Annals of Surgery, 2020, 271, e21-e93.	4.2	290
24	Executive Summary of the American Association of Endocrine Surgeons Guidelines for the Definitive Surgical Management of Thyroid Disease in Adults. Annals of Surgery, 2020, 271, 399-410.	4.2	33
25	BRAF <sup>V600E</sup> Mutation is Associated with an Increased Risk of Papillary Thyroid Cancer Recurrence. World Journal of Surgery, 2020, 44, 2685-2691.	1.6	26
26	Patient-Reported Quality-of-Life Outcome Measures in the Thyroid Cancer Population. Thyroid, 2020, 30, 1414-1431.	4.5	30
27	Is Less More? A Microsimulation Model Comparing Cost-effectiveness of the Revised American Thyroid Association's 2015 to 2009 Guidelines for the Management of Patients With Thyroid Nodules and Differentiated Thyroid Cancer. Annals of Surgery, 2020, 271, 765-773.	4.2	22
28	A Long, Unnerving Road: Malpractice Claims Involving the Surgical Management of Thyroid and Parathyroid Disease. World Journal of Surgery, 2019, 43, 2850-2855.	1.6	11
29	Does overlapping surgery result in worse surgical outcomes? AÂsystematic review and meta-analysis. American Journal of Surgery, 2019, 218, 181-191.	1.8	6
30	Reply to "Impact of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP) on the Outcomes of Lobectomy― Annals of Surgical Oncology, 2019, 26, 307-308.	1.5	2
31	Circulating <i>BRAF<sup>V600E</sup></i> Levels Correlate with Treatment in Patients with Thyroid Carcinoma. Thyroid, 2018, 28, 328-339.	4.5	20
32	A Meta-Analysis of the Association Between Radiation Therapy and Survival for Surgically Resected Soft-Tissue Sarcoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 348-356.	1.3	9
33	Evaluating the projected surgical impact of reclassifying noninvasive encapsulated follicular variant of papillary thyroid cancer as noninvasive follicular thyroid neoplasm with papillary-like nuclear features. Surgery, 2018, 163, 60-65.	1.9	30
34	Impact of Extent of Surgery on Tumor Recurrence and Survival for Papillary Thyroid Cancer Patients. Annals of Surgical Oncology, 2018, 25, 2520-2525.	1.5	47
35	Widespread Chromosomal Losses and Mitochondrial DNA Alterations as Genetic Drivers in Hürthle Cell Carcinoma. Cancer Cell, 2018, 34, 242-255.e5.	16.8	185
36	Association of Insurance Expansion With Surgical Management of Thyroid Cancer. JAMA Surgery, 2017, 152, 734.	4.3	20

CARRIE C LUBITZ

#	Article	IF	CITATIONS
37	Reassessing risks and benefits of living kidney donors with a history of thyroid cancer. Clinical Transplantation, 2017, 31, e13114.	1.6	3
38	Measurement and Variation in Estimation of Quality of Life Effects of Patients Undergoing Treatment for Papillary Thyroid Carcinoma. Thyroid, 2017, 27, 197-206.	4.5	37
39	Editorial: Complex decision making in thyroid cancer: Costs and consequences–is less more?. Surgery, 2017, 161, 134-136.	1.9	10
40	The Changing Landscape of Primary, Secondary, and Tertiary Hyperparathyroidism: Highlights from the American College of Surgeons Panel, "What's New for the Surgeon Caring for Patients with Hyperparathyroidism― Journal of the American College of Surgeons, 2016, 222, 1240-1250.	0.5	26
41	The changing landscape of papillary thyroid cancer: Epidemiology, management, and the implications for patients. Cancer, 2016, 122, 3754-3759.	4.1	92
42	The Truth about Double Adenomas: Incidence, Localization, and Intraoperative Parathyroid Hormone. Journal of the American College of Surgeons, 2016, 222, 1044-1052.	0.5	25
43	Detection of Circulating BRAF in Patients with Papillary Thyroid Carcinoma. Journal of Molecular Diagnostics, 2016, 18, 100-108.	2.8	30
44	Editorial: Is molecular testing cost effective? It depends. Surgery, 2016, 159, 130-131.	1.9	1
45	Should specific patient clinical characteristics discourage adrenal surgeons from performing laparoscopic transperitoneal adrenalectomy?. Surgery, 2016, 159, 240-249.	1.9	26
46	<i>BRAF<sup>V600E</sup></i> Is Correlated with Recurrence of Papillary Thyroid Microcarcinoma: A Systematic Review, Multi-Institutional Primary Data Analysis, and Meta-Analysis. Thyroid, 2016, 26, 248-255.	4.5	88
47	Cost-Effectiveness of Screening for Primary Aldosteronism and Subtype Diagnosis in the Resistant Hypertensive Patients. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 621-630.	2.2	45
48	Annual financial impact of wellâ€differentiated thyroid cancer care in the United States. Cancer, 2014, 120, 1345-1352.	4.1	159
49	Hobnail Variant of Papillary Thyroid Carcinoma: An Institutional Case Series and Molecular Profile. Thyroid, 2014, 24, 958-965.	4.5	78
50	Surgeons and Patients Disagree on the Potential Consequences of Hypoparathyroidism. Endocrine Practice, 2014, 20, 427-446.	2.1	46
51	A multi-institutional international study of risk factors for hematoma after thyroidectomy. Surgery, 2013, 154, 1283-1291.	1.9	86
52	Surgery for Graves' disease: a 25-year perspective. American Journal of Surgery, 2013, 206, 669-673.	1.8	25
53	Management of Thyroid Nodules with Atypical Cytology on Fine-needle Aspiration Biopsy. Annals of Surgical Oncology, 2013, 20, 60-65.	1.5	76
54	Diagnostic Yield of Nondiagnostic Thyroid Nodules Is Not Altered by Timing of Repeat Biopsy. Thyroid, 2012, 22, 590-594.	4.5	44

4

CARRIE C LUBITZ

#	Article	IF	CITATIONS
55	BRAF status adds incremental value to current risk classification systems in predicting papillary thyroid carcinoma recurrence. Surgery, 2012, 152, 984-990.	1.9	59
56	Preoperative Localization Strategies for Primary Hyperparathyroidism: An Economic Analysis. Annals of Surgical Oncology, 2012, 19, 4202-4209.	1.5	90
57	Accuracy of 4-dimensional computed tomography in poorly localized patients with primary hyperparathyroidism. Surgery, 2010, 148, 1129-1138.	1.9	98
58	Clinical and Cytological Features Predictive of Malignancy in Thyroid Follicular Neoplasms. Thyroid, 2010, 20, 25-31.	4.5	55
59	Surgical drains can be safely avoided in lateral neck dissections for papillary thyroid cancer. American Journal of Surgery, 2010, 199, 485-490.	1.8	16
60	Identification of borderline thyroid tumors by gene expression array analysis. Cancer, 2009, 115, 5421-5431.	4.1	40
61	Microarray Analysis of Thyroid Nodule Fine-Needle Aspirates Accurately Classifies Benign and Malignant Lesions. Journal of Molecular Diagnostics, 2006, 8, 490-498.	2.8	57
62	Gene expression profiling of thyroid tumors—clinical applicability. Nature Clinical Practice Endocrinology and Metabolism, 2006, 2, 472-473.	2.8	6
63	Molecular analysis of minimally invasive follicular carcinomas by gene profiling. Surgery, 2005, 138, 1042-1049.	1.9	38